TrialBlood advances2023

Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study.

Adam J Olszewski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.